Background: The epidemiology of multiple drug intolerance syndrome (MDIS) and
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| INTRODUCTION
Drug allergies are commonly reported by patients and documented in medical charts. [1] [2] [3] [4] [5] Patients reporting any drug allergy history are likely to report allergies to multiple drug classes. 2, 6 Drug allergies documented in the electronic health record (EHR) can be intolerances, toxicities, or hypersensitivities (ie, immunologic reactions). 7 While definitions have varied, 2, [8] [9] [10] multiple drug intolerance syndrome (MDIS) describes patients who have nonimmunologic reactions to three or more drug classes, 2, 11 and multiple drug allergy syndrome (MDAS) describes patients with hypersensitivity reactions to two or more drug classes. [12] [13] [14] [15] A third term, multiple drug hypersensitivity (MDH) describes patients with proven hypersensitivities to two or more distinct drugs after drug allergy evaluation. 9 MDIS occurs in about 2% of patients. 2, 11 While the prevalence of MDAS remains unknown, at least 5% of patients report one or more drug hypersensitivity, 1, 2, 16, 17 and at least 10% of those patients (or 0.5% of patients) have MDAS. 6, 18 Commonly described drug culprits in both MDIS and MDAS include antibiotics, antiepileptics, hypnotics, antidepressants, local anesthetics, glucocorticoids, opiates, and nonsteroidal anti-inflammatory drugs (NSAIDs). 10, 11, 19, 20 Urticaria and angioedema are the most commonly described reactions in MDAS, although severe reactions (eg, bullous exanthema, StevensJohnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome) have also been described in MDAS. 5, 6, 9, 10, 19 Risk factors for MDIS include female sex, older age, greater weight, prior hospitalizations, and multiple medical comorbidities. 2, 11 Female sex has also been identified as a risk factor for MDAS. 19 ,21,22
G R A P H I C A L A B S T R A C T
In this study, we used electronic health record data from 746 888 patients in a large US healthcare system to determine the prevalence of multiple drug intolerance syndrome (MDIS, 6%) and multiple drug allergy syndrome (MDAS, 1%). Patients with both MDIS and MDAS comprised 0.4% of the population (upper left). Common drug classes for MDIS and MDAS were penicillins, opiates, sulfonamides, and nonsteroidal antiinflammatory drugs (upper right). We assessed the association between MDIS and MDAS and anxiety and depression while adjusting for confounding variables (bottom right). MDIS was associated with both depression and anxiety; patients with both depression and anxiety had a twofold increased odds of MDIS. MDAS was associated with a 40% increased odds of depression, but there was no consistent relationship with anxiety.
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Prior studies have suggested associations between MDIS and/or MDAS and various psychiatric comorbidities, including anxiety, depression, alexithymia, and somatization. [22] [23] [24] However, to date, no clear relationship is defined.
In this study, we used longitudinal EHR data to describe the epidemiology of reported MDIS and MDAS in a large United States healthcare system and evaluated the relationship between anxiety, depression, MDIS, and MDAS.
| ME TH ODS
We performed a retrospective study of patients seen at Partners 
| MDIS and MDAS
Patients with MDIS had intolerance or side-effect reactions to three or more drug classes; patients with MDAS had reactions to two or more drug classes with a possible immunologic mechanism. To identify reactions with a possible immunologic mechanism (ie, hypersensitivity reactions [HSRs]), we used both coded and free-text (noncoded) reaction entries in PEAR and keyword searches (Table S1 ). We considered reactions that mapped to hypotension, shock, arrest, and arrhythmia with anaphylaxis. Bronchospasm, wheezing, and asthma were considered with shortness of breath. All entries of "rash" without further description were assumed to be delayed-type eruptions/type IV HSRs. To categorize drug allergens, we performed drug and drug class keywords searches, similarly using coded and free-text data. [1] [2] [3] 11 We used an iterative semiautomated methodology, which involved manual review and validation of groupings until >90% of MDAS allergens were classified.
MDIS and MDAS were defined at the end of the study period (ie, 2015), but also evaluated at the beginning of the study period (ie, 2008) in sensitivity analyses, as the timing of reactions is unknown for PEAR entries and entries can be added and removed over time. 27 Because of varied literature definitions of MDIS and MDAS (Table S2) , 2, 15, 28, 29 we also evaluated alternative definitions of MDIS (two of more drug class intolerances) and MDAS (three of more drug class hypersensitivities) in sensitivity analyses.
| Assessment of variables
The primary variables of interest were anxiety and depression.
Anxiety was defined by patients who had a relevant International
Classification of Diseases, ninth edition (ICD-9) code and a prescription of anxiolytic medication within 1 year of that code from 2008 through 2015 (Table S3) . Depression was similarly defined by ICD-9 codes and an antidepressant prescription. Because many patients with mild anxiety and/or depression do not receive pharmacologic treatment, 30, 31 we also assessed alternative definitions of anxiety and depression that required only an ICD-9 code in sensitivity analyses. As anxiety and depression often coexist, 32 we assessed anxiety and depression in four distinct groups: anxiety only, depression only, both anxiety and depression, and neither anxiety nor depression.
Other variables of interest included age (at study onset), sex, race/ethnicity, and marital status, defined from EHR demographic tables. Smoking, alcohol use, and drug use were defined by the presence of a relevant ICD-9 code or documentation of use in the EHR preventative health information. Individual medical comorbidities (eg, chronic urticaria angioedema and autoimmune diseases) and Charlson comorbidity index (CCI) were defined using ICD-9 codes. All ICD-9 codes were informed by prior studies, when available (Table S3 ). Allergies to vaccines, foods, and environmental allergens were defined from PEAR. Healthcare utilization was identified from EHR encounter tables and considered as another proxy for overall health and degree of exposure to medications. To determine the stability of our conclusions, we conducted various sensitivity analyses around the definitions of the psychiatric conditions and MDIS/MDAS and models with different covariates.
| Statistical analyses
We used a stratified analysis to investigate whether the effect of anxiety and depression on drug class intolerances/hypersensitivities increased with the number of drug class intolerances/hypersensitivities. We compared groups of patients with a specific number of drug class intolerances and hypersensitivities to the common control group using separate logistic regression models.
All P values were 2-sided. While P < .05 was considered statistically significant, we only highlighted clinically important effects due to the large cohort size. All analyses were conducted in SAS 9.4
(Cary, NC, USA).
| RESULTS

| Prevalence, drugs, and reactions
Among 746 
| Cohort characteristics
MDIS only and MDAS only patients were older, and more commonly female and white, compared to patients with neither MDIS nor MDAS (comparator patients, Table 2 ). Marital status differed between patient groups, with married and single being most frequent in the patients with MDAS, and widowed being most frequent in comparator patients. Smoking was most common in MDIS and least common in comparator patients. Alcohol use and drug use were infrequently identified overall, but most frequent in patients with MDIS compared to patients with MDAS and comparators.
Other allergies were more common in patients with MDIS and MDAS than comparators. Chronic urticaria/angioedema was most common in MDAS, compared to MDIS and comparators. All other medical comorbidities were most prevalent in MDIS. CCI was similar in MDIS and MDAS and higher than in the comparators patients.
Patients with MDAS had frequent outpatient healthcare utilization; patients with MDIS had the most frequent inpatient and emergency room visits.
| Anxiety and depression
In unadjusted analyses, patients with psychiatric comorbidities had The association between anxiety and MDAS was inconsistent (Table S5 ). The OR ranged from 1.08 to 1.26, without statistical significance in all but two analyses. Depression was consistently associated with MDAS across all sensitivity analyses with OR ranging from 1.26 to 1.44. Having both anxiety and depression was not significantly associated with increased odds of MDAS across sensitivity analyses.
The magnitude of the OR for anxiety was greater with the number of drug class intolerances reported (P for trend<.001, Figure 2 ).
For patients with one drug class intolerance, odds ratio of anxiety was 1.48; for patients with two drug class intolerances, odds ratio of anxiety was 1.64; for patients with three drug class intolerances, odds ratio of anxiety was 1.72; for patients with four drug class intolerances, odds ratio of anxiety was 1.77; and for patients with five drug class intolerances, odds ratio of anxiety was 1.81. There was no significant relationship between number of drug class hypersensitivities and anxiety (P for trend=.12).
The magnitude of the OR for depression was greater with the number of drug class intolerances reported (P for trend <.001, Figure 2 ). For patients with one drug class intolerance, odds ratio of depression was 1.36; for patients with two drug class intolerances, odds ratio of depression was 1.42; for patients with three drug class intolerances, odds ratio of depression was 1.46; for patients with four drug class intolerances, odds ratio of depression was 1.45; and for patients with five drug class intolerances, odds ratio of depression was 1.46. There was no significant linear relationship between the effect of anxiety and number of drug class hypersensitivities (P for trend=.15). Organ-specific reactions include acute interstitial nephritis (n = 667), immune-mediated hepatitis (n = 39), aseptic meningitis (n = 6), and interstitial pneumonitis (n = 5) 
| Association with other variables
T A B L E 2 Characteristics of patients with multiple drug intolerance syndrome (MDIS) and multiple drug allergy syndrome (MDAS)
MDIS
| DISCUSSION
In this large retrospective study of patients in an integrated US healthcare system, 6% of the population had documented MDIS and 1% had documented MDAS; <0.5% had both MDIS and MDAS documented.
While anxiety and depression were associated with MDIS, depression, but not anxiety, was associated with MDAS. The odds of anxiety and depression increased with the number of drug class intolerances patients had, but no similar relationship between number of drug class hypersensitivities and anxiety was identified. Both MDIS and MDAS were associated with older age, female sex, white race, increased healthcare utilization, chronic urticaria, and autoimmune disease.
To our knowledge, this is the first large data report that distinguished MDIS from MDAS using reported reactions, and the first prevalence estimate of MDAS, using EHR data (1%). 8, 9 While we found that 6% of patients had MDIS, prior studies identified prevalences of 2% among patients generally, and 5% among hospitalized patients reporting any medication intolerance. and consistent with prior common causative drugs described in MDIS and MDAS. 11, 19, 20 While HSRs in patients with MDAS not surprisingly included urticaria, angioedema, and rash, we observed a high prevalence of SCAR, consistent with early MDAS descriptions as a syndrome that occurred after drug reaction eosinophilia and systemic symptoms syndrome or other severe reactions. 6, 9, 10, 19 Depression affects approximately 10% of Americans, with a lifetime prevalence from 16% to 30%. [36] [37] [38] We found that depression was associated with both MDIS and MDAS, with a 50% and 40% increased odds, respectively. The association remained strong and consistent for both MDIS and MDAS in all sensitivity analyses. A prior retrospective study in a large US healthcare system found that psychiatry visits were more common in patients with MDIS (from 38% to 47% depending on MDIS severity) compared to patients with no drug allergies (20%). 2 Smaller, prospective studies using psychodiagnostic tests reported high levels of depression-as well as anxiety, lower quality of life, and alexithymia-in patients with drug allergies compared to controls. 22, 23 Our study confirms a significant association between depression and MDIS and MDAS. Although selective serotonin reuptake inhibitors (SSRIs, the most commonly used antidepressants) are commonly reported as causing drug intolerances and can also cause HSRs, given that only 7% of patients with MDIS were intolerant to SSRIs and 1% of patients with MDAS reported an This study has several potential limitations. The use of EHRbased data can lead to miscategorization and lack of specificity. We were reliant on billing codes for patient diagnoses, including the primary variables of interest (depression and anxiety). However, codes used in this study were informed by prior studies, and we performed a variety of sensitivity analyses around variable definitions to assess the stability of our findings. EHR allergies in PEAR were used to define MDIS, MDAS, and reaction types, but EHR allergy documentation is often inaccurate. Reactions often lack specificity, and data are uncommonly entered by allergy specialists and verified by allergy testing. 7 Covariate assessment may be incomplete because PHS is not a closed healthcare system; however, by establishing patient visit criteria over the study horizon, we improved data capture opportunities. However, without knowing when the reported allergies occurred, some important covariates, such as concomitant medications, could not be assessed in risk factor analyses. We were also unable to identify whether the diagnosis of MDIS or MDAS was before or after psychiatric diagnoses. Finally, these data represent one healthcare system in the northeastern United States, and findings may not be generalizable to other settings.
In summary, we identified a population of patients with MDIS and MDAS using EHR data; patients had drug culprits and reactions that were generally similar to previously described cohorts that used different identification and verification methods. We found a consistent association between anxiety and depression and MDIS; by contrast, depression, but not anxiety, was associated with MDAS. Our findings emphasize the importance of psychological screening and support for patients with MDIS and MDAS and identify an expanded role for medication tolerance testing. Physiologic causes that may underlie MDAS warrant additional prospective study. Finally, given the heterogeneity of definitions proposed and used for patients with multiple drug intolerance and hypersensitivity, to facilitate future MDIS, MDAS, and MDH research, adoption of standardized terminology is warranted.
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